New cancer clinical trial: Study to Evaluate the Therapeautic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Published on: December 29, 2017 at 10:00AM
Condition:   Solid Tumors
Interventions:   Drug: RO6874281;   Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Sponsor:   Hoffmann-La Roche
Not yet recruiting
http://ift.tt/2zOLzEO